Monthly Archives: August 2020

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Oculopharyngeal Muscular Dystrophy Treatment market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Oculopharyngeal Muscular Dystrophy Treatment market Continue reading →

Text size Newly-hired analyst Danielle Brill launched coverage at Raymond James this week with a 490-page survey of her favorite biotech stocks. Atop the list are hematology drugmaker Acceleron Pharma and the gene therapy developer uniQure. Brill thinks Acceleron (ticker: XLRN) could rise at least 60%, while uniQure (QURE) could nearly double. Continue reading →

PALM BEACH, Fla., Aug. 26, 2020 /PRNewswire/ -- Although various market revenue projections may differ in the total dollar figures, the reports in the triple negative breast cancer (TNBC) treatment market all predict a sustainable growth oner the next several years to come. A previous report from Mind Aspire Market Research was trumped by another report from Future Wise Research Continue reading →

Letters to the Editor Aug 29, 2020 To the editor: They didnt give me the right to try experimental treatments, Mr. President. You did and without you, Id have died waiting for them to be approved, said Natalie Harp on Monday night at the Republican National Convention Continue reading →

- Integrated program encompasses formulation development, drug substances and drug product manufacturing - Project involves three Piramal Pharma Solutions (PPS) sites in India - New, specialized technologies have been added in a dedicated area MUMBAI, India, Aug. 27, 2020 /PRNewswire/ -- Piramal Pharma Solutions, a leading contract development and manufacturing organization (CDMO), today announced that the company will be partnering with Epirium Bio on an exclusive manufacturing relationship for new orphan drugs targeting rare diseases with high unmet needs. The Piramal Pharma Solutions (PPS) team is providing Epirium with an integrated program that encompasses formulation development, supply of APIs and intermediates, chemistry development and manufacturing, and solid oral dosage form drug product. Continue reading →

The next 73 days are going to be very difficult for Stephen Hahn. As the Nov. 3 election nears, the Food and Drug Administration commissioner can expect intensifying pressure from President Trump to approve a vaccine or a drug to combat Covid-19. Continue reading →